George D Mellick

List of Publications by Year
in descending order

184 papers	9,355 citations	46918 47 h-index	49773 87 g-index
192 all docs	192 docs citations	192 times ranked	11485 citing authors

#	Article	IF	Citations
1	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	1.5	21
2	Changes in pallidal neural activity following long-term symptom improvement from botulinum toxin treatment in DYT6 dystonia: a case report. Journal of Medical Case Reports, 2022, 16, 15.	0.4	1
3	Strong Predictive Algorithm of Pathogenesis-Based Biomarkers Improves Parkinsonâ€™s Disease Diagnosis. Molecular Neurobiology, 2022, 59, 1476-1485.	1.9	3
4	Hesperine, a new imidazole alkaloid and Î±-synuclein binding activity of 1-methyl-1,2,7,8-tetrahydro-2,8-dioxoadenosine from the marine sponge Clathria (Thalysias) cf. hesperia. Results in Chemistry, 2022, 4, 100302.	0.9	4
5	Australian Parkinsonâ€™s Genetics Study (APGS): pilot (n=1532). BMJ Open, 2022, 12, e052032.	0.8	1
6	Phlegmacaritones A and B, a Pair of Serratane-Related Triterpenoid Epimers with an Unprecedented Carbon Skeleton from Phlegmariurus carinatus. Journal of Natural Products, 2022, 85, 899-909.	1.5	6
7	Proteomic profiling of idiopathic Parkinson's disease primary patient cells by SWATHâ€MS. Proteomics - Clinical Applications, 2022, 16, e2200015.	0.8	3
8	Mitochondrial and Clearance Impairment in p.<scp>D620N VPS35</scp> Patientâ€Derived Neurons. Movement Disorders, 2021, 36, 704-715.	2.2	32
9	A Rare Case of Green Gelatinous Mass Formation on a Deep Brain Stimulation Implantable Pulse Generator. Journal of Movement Disorders, 2021, 14, 81-83.	0.7	1
10	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	3.8	49
11	Hunting for Familial Parkinsonâ€™s Disease Mutations in the Post Genome Era. Genes, 2021, 12, 430.	1.0	4
12	Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease. Frontiers in Neurology, 2021, 12, 648417.	1.1	5
13	Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. Redox Biology, 2021, 41, 101896.	3.9	75
14	Calcium channels and iron metabolism: A redox catastrophe in Parkinson's disease and an innovative path to novel therapies?. Redox Biology, 2021, 47, 102136.	3.9	4
15	The Queensland Parkinsonâ€™s Project: An Overview of 20 Years of Mortality from Parkinsonâ€™s Disease. Journal of Movement Disorders, 2021, 14, 34-41.	0.7	12
16	Sycosterol A, an Î±-Synuclein Inhibitory Sterol from the Australian Ascidian Sycozoa cerebriformis. Journal of Natural Products, 2021, 84, 3039-3043.	1.5	6
17	Establishing historical sample data is essential for identification of unaccounted Australian soldiers from WWI, WWII, and the Korean War. Australian Journal of Forensic Sciences, 2020, 52, 529-536.	0.7	2
18	Factors related to sleep disturbances for individuals with Parkinsonâ€™s disease: a regional perspective. International Psychogeriatrics, 2020, 32, 827-838.	0.6	3

#	Article	IF	Citations
19	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. Acta Pharmacologica Sinica, 2020, 41, 483-498.	2.8	30
20	O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on Î±-synuclein aggregation. Bioorganic Chemistry, 2020, 94, 103389.	2.0	10
21	Differential patterns of internally generated responses in parkinsonian disorders. Neuropsychologia, 2020, 146, 107569.	0.7	5
22	Chemical constituents from Macleaya cordata (Willd) R. Br. and their phenotypic functions against a Parkinsonâ€™s disease patient-derived cell line. Bioorganic and Medicinal Chemistry, 2020, 28, 115732.	1.4	9
23	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	2.2	57
24	Anti-prion and Î±-Synuclein Aggregation Inhibitory Sterols from the Sponge Lamellodysidea cf. chlorea. Journal of Natural Products, 2020, 83, 3751-3757.	1.5	8
25	Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson's disease carrying the p.D620N mutation in VPS35. Stem Cell Research, 2020, 45, 101776.	0.3	5
26	A Grand Challenge. 3. Unbiased Phenotypic Function of Metabolites from Australia Plants Gloriosa superba and Alangium villosum against Parkinsonâ€™s Disease. Journal of Natural Products, 2020, 83, 1440-1452.	1.5	5
27	Evidence of a Recessively Inherited CCN3 Mutation as a Rare Cause of Early-Onset Parkinsonism. Frontiers in Neurology, 2020, 11, 331.	1.1	1
28	Analysis of DNA methylation associates the cystineâ€“glutamate antiporter SLC7A11 with risk of Parkinsonâ€™s disease. Nature Communications, 2020, 11, 1238.	5.8	85
29	Genetic Analysis of RAB39B in an Early-Onset Parkinson's Disease Cohort. Frontiers in Neurology, 2020, 11, 523.	1.1	11
30	Novel Furan-2-yl-1H-pyrazoles Possess Inhibitory Activity against Î±-Synuclein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2303-2315.	1.7	9
31	Perspective: Current Pitfalls in the Search for Future Treatments and Prevention of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 686.	1.1	6
32	An Ensemble Approach to Modelling the Combined Effect of Risk Factors on Age at Parkinsonâ€™s Disease Onset. Lecture Notes in Mathematics, 2020, , 275-302.	0.1	0
33	Design, Synthesis, and Biological Evaluation of Bimodal Glycopeptides as Inhibitors of Neurotoxic Protein Aggregation. Proceedings (mdpi), 2019, 22, .	0.2	0
34	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414
35	Singing for people with Parkinson's disease. The Cochrane Library, 2019, , .	1.5	1
36	Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. Genome Medicine, 2019, 11, 54.	3.6	191

#	Article	IF	Citations
37	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
38	Identification of a New Î±-Synuclein Aggregation Inhibitor via Mass Spectrometry Based Screening. ACS Chemical Neuroscience, 2019, 10, 2683-2691.	1.7	24
39	O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chemical Neuroscience, 2019, 10, 2209-2221.	1.7	56
40	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	2.5	83
41	Depression symptomatology correlates with event-related potentials in Parkinson's disease: An affective priming study. Journal of Affective Disorders, 2019, 245, 897-904.	2.0	10
42	Wild-type and mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2) associate with subunits of the translocase of outer mitochondrial membrane (TOM) complex. Experimental Cell Research, 2019, 375, 72-79.	1.2	4
43	Pipeline to gene discovery - Analysing familial Parkinsonism in the Queensland Parkinson's Project. Parkinsonism and Related Disorders, 2018, 49, 34-41.	1.1	17
44	Sulfotransferase 1A3/4 copy number variation is associated with neurodegenerative disease. Pharmacogenomics Journal, 2018, 18, 209-214.	0.9	19
45	Dexamethasone Inhibits Copper-Induced Alpha-Synuclein Aggregation by a Metallothionein-Dependent Mechanism. Neurotoxicity Research, 2018, 33, 229-238.	1.3	14
46	Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females. Movement Disorders, 2018, 33, 1178-1181.	2.2	20
47	How Well Do Caregivers Detect Depression and Anxiety in Patients With Parkinson Disease?. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 227-236.	1.2	14
48	Design and Synthesis of Natural Product Inspired Libraries Based on the Three-Dimensional (3D) Cedrane Scaffold: Toward the Exploration of 3D Biological Space. Journal of Medicinal Chemistry, 2018, 61, 6609-6628.	2.9	20
49	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	3.7	2
50	Role of the VPS35 D620N mutation in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 10-18.	1.1	24
51	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	3.7	116
52	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of Aging, 2017, 49, 217.e1-217.e4.	1.5	7
53	Mini-review on initiatives to interfere with the propagation and clearance of alpha-synuclein in Parkinsonâ€™s disease. Translational Neurodegeneration, 2017, 6, 33.	3.6	10
54	N400 and emotional word processing in Parkinsonâ€™s disease.. Neuropsychology, 2017, 31, 585-595.	1.0	11

#	Article	IF	Citations
55	Nrf2 and Parkinsonâ€™s Disease. , 2016, , .		0
56	A door-to-door survey to estimate the prevalence of Parkinsonism in Pakistan. Neuropsychiatric Disease and Treatment, 2016, 12, 1499.	1.0	7
57	Disease-specific anxiety symptomatology in Parkinson's disease. International Psychogeriatrics, 2016, 28, 1153-1163.	0.6	44
58	Nrf2: a modulator of Parkinsonâ€™s disease?. Journal of Neural Transmission, 2016, 123, 611-619.	1.4	73
59	A Grand Challenge. 2. Phenotypic Profiling of a Natural Product Library on Parkinsonâ€™s Patient-Derived Cells. Journal of Natural Products, 2016, 79, 1982-1989.	1.5	11
60	Identification of genetic modifiers of age-at-onset for familial Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, 3849-3862.	1.4	44
61	Meeting the Challenge: Using Cytological Profiling to Discover Chemical Probes from Traditional Chinese Medicines against Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 1628-1634.	1.7	12
62	A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinsonâ€™s Disease. Journal of Natural Products, 2016, 79, 353-361.	1.5	19
63	Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0154544.	1.1	13
64	Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 155-162.	0.8	28
65	Kororamide B, a brominated alkaloid from the bryozoan Amathia tortuosa and its effects on Parkinson's disease cells. Tetrahedron, 2015, 71, 7879-7884.	1.0	13
66	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85, 1283-1292.	1.5	25
67	Comprehensive Assessment of Genetic Sequence Variants in the Antioxidant â€˜Master Regulatorâ€™ Nrf2 in Idiopathic Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0128030.	1.1	28
68	DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro. Movement Disorders, 2014, 29, 1606-1614.	2.2	79
69	Global investigation and meta-analysis of the C9orf72 (G ₄ C ₂) _n repeat in Parkinson disease. Neurology, 2014, 83, 1906-1913.	1.5	56
70	Risk factors for idiopathic dystonia in Queensland, Australia. Journal of Clinical Neuroscience, 2014, 21, 2145-2149.	0.8	11
71	Mutations in RAB39B Cause X-Linked Intellectual Disability and Early-Onset Parkinson Disease with Î±-Synuclein Pathology. American Journal of Human Genetics, 2014, 95, 729-735.	2.6	207
72	Frontispiece: NMR Fingerprints of the Drug-like Natural-Product Space Identify Iotrochotazineâ€…A: A Chemical Probe to Study Parkinsonâ€™s Disease. Angewandte Chemie - International Edition, 2014, 53, n/a-n/a.	7.2	0

#	Article	IF	Citations
73	Improved nutritional status is related to improved quality of life in Parkinsonâ€™s disease. BMC Neurology, 2014, 14, 212.	0.8	43
74	Psychiatric disorders in idiopathic-isolated focal dystonia. Journal of Neurology, 2014, 261, 668-674.	1.8	28
75	Alphaâ€synuclein repeat variants and survival in Parkinson's disease. Movement Disorders, 2014, 29, 1053-1057.	2.2	14
76	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	1.5	36
77	Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin. Neurobiology of Disease, 2014, 62, 172-178.	2.1	74
78	The Vps35 <scp>D620N</scp> Mutation Linked to Parkinson's Disease Disrupts the Cargo Sorting Function of Retromer. Traffic, 2014, 15, 230-244.	1.3	186
79	Knowledge and attitudes towards genetic testing in those affected with Parkinsonâ€™s disease. Journal of Community Genetics, 2014, 5, 167-177.	0.5	16
80	Rare POLG1 CAG variants do not influence Parkinson's disease or polymerase gamma function. Mitochondrion, 2014, 15, 65-68.	1.6	8
81	NMR Fingerprints of the Drugâ€like Naturalâ€Product Space Identify Iotrochotazineâ€…A: A Chemical Probe to Study Parkinsonâ€™s Disease. Angewandte Chemie - International Edition, 2014, 53, 6070-6074.	7.2	56
82	Lack of reproducibility in re-evaluating associations between GCH1 polymorphisms and Parkinson's disease and isolated dystonia in an Australian caseâ€“control group. Parkinsonism and Related Disorders, 2014, 20, 668-670.	1.1	9
83	Frontispiz: NMR Fingerprints of the Drug-like Natural-Product Space Identify Iotrochotazineâ€…A: A Chemical Probe to Study Parkinsonâ€™s Disease. Angewandte Chemie, 2014, 126, n/a-n/a.	1.6	0
84	Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinsonâ€™s disease. Quality of Life Research, 2013, 22, 1065-1072.	1.5	22
85	Populationâ€specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	2.2	30
86	Nutrition screening and assessment in Parkinson's disease: AÂcomparison of methods. E-SPEN Journal, 2013, 8, e187-e192.	0.5	11
87	Screening for rare sequence variants in the THAP1 gene in a primary dystonia cohort. Movement Disorders, 2013, 28, 1752-1753.	2.2	5
88	New evidence for, and challenges in, linking small <scp>CGG</scp> repeat expansion <scp>FMR1</scp> alleles with Parkinson's disease. Clinical Genetics, 2013, 84, 382-385.	1.0	19
89	Malnutrition in a Sample of Community-Dwelling People with Parkinsonâ€™s Disease. PLoS ONE, 2013, 8, e53290.	1.1	62
90	Markers of Disease Severity Are Associated with Malnutrition in Parkinson's Disease. PLoS ONE, 2013, 8, e57986.	1.1	53

#	Article	IF	Citations
91	Probabilistic subgroup identification using Bayesian finite mixture modelling: A case study in Parkinson's disease phenotype identification. Statistical Methods in Medical Research, 2012, 21, 563-583.	0.7	5
92	Subcortical Activity during Verbal Selection and Suppression in Parkinson's Disease. Procedia, Social and Behavioral Sciences, 2012, 61, 50-51.	0.5	0
93	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	1.5	94
94	Evaluating industry-based doctoral research programs: perspectives and outcomes of Australian Cooperative Research Centre graduates. Studies in Higher Education, 2012, 37, 843-858.	2.9	30
95	Common polymorphisms in dystonia-linked genes and susceptibility to the sporadic primary dystonias. Parkinsonism and Related Disorders, 2012, 18, 351-357.	1.1	20
96	Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.	1.5	119
97	Neuroferritinopathy. Parkinsonism and Related Disorders, 2012, 18, 909-915.	1.1	92
98	Validity and reliability of the Geriatric Anxiety Inventory in Parkinson's disease*^{â€}. Australasian Journal on Ageing, 2012, 31, 13-16.	0.4	49
99	Assessment methods and factors associated with depression in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 208-210.	0.3	28
100	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	1.5	56
101	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiology of Aging, 2011, 32, 2108.e1-2108.e5.	1.5	23
102	The Disposition of Aspirin and Salicylic Acid in the Isolated Perfused Rat Liver: the Effect of Normal and Retrograde Flow on Availability and Mean Transit Time. Journal of Pharmacy and Pharmacology, 2011, 48, 738-743.	1.2	14
103	Impulse-response Studies on Tracer Doses of [14C]Lignocaine and its Multiple Metabolites in the Perfused Rat Liver. Journal of Pharmacy and Pharmacology, 2011, 49, 1008-1018.	1.2	0
104	The Effect of Protein Binding on the Hepatic First Pass of O-Acyl Salicylate Derivatives in the Rat. Journal of Pharmacy and Pharmacology, 2011, 50, 63-69.	1.2	6
105	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. Journal of Alzheimer's Disease, 2011, 25, 395-415.	1.2	24
106	NRF2 Activation Restores Disease Related Metabolic Deficiencies in Olfactory Neurosphere-Derived Cells from Patients with Sporadic Parkinson's Disease. PLoS ONE, 2011, 6, e21907.	1.1	81
107	Caffeine and Parkinsonâ€™s disease: are we getting our fix on risk-modifying gene-environment interactions?. European Journal of Neurology, 2011, 18, 671-672.	1.7	5
108	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a caseâ€“control study. Lancet Neurology, The, 2011, 10, 898-908.	4.9	294

#	Article	IF	Citations
109	Factors associated with depression in Parkinson's disease. Journal of Affective Disorders, 2011, 132, 82-88.	2.0	142
110	Single and dual task gait training in people with Parkinson's Disease: A protocol for a randomised controlled trial. BMC Neurology, 2011, 11, 90.	0.8	49
111	Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Annals of Neurology, 2011, 69, 778-792.	2.8	92
112	Stem Cell Models for Biomarker Discovery in Brain Disease. International Review of Neurobiology, 2011, 101, 239-257.	0.9	4
113	Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Human Molecular Genetics, 2011, 20, 615-627.	1.4	155
114	Teaching Neuro Images : Neuroferritinopathy. Neurology, 2011, 77, e107.	1.5	3
115	Variance of Gene Expression Identifies Altered Network Constraints in Neurological Disease. PLoS Genetics, 2011, 7, e1002207.	1.5	132
116	Nonâ€replication of association for six polymorphisms from metaâ€analysis of genomeâ€wide association studies of Parkinson's disease: Largeâ€scale collaborative study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 220-228.	1.1	16
117	Anxiety disorders in Parkinson's disease: Prevalence and risk factors. Movement Disorders, 2010, 25, 838-845.	2.2	317
118	Exploiting the potential of molecular profiling in Parkinsonâ€™s disease: current practice and future probabilities. Expert Review of Molecular Diagnostics, 2010, 10, 1035-1050.	1.5	14
119	Disease-specific, neurosphere-derived cells as models for brain disorders. DMM Disease Models and Mechanisms, 2010, 3, 785-798.	1.2	175
120	A Cross-Study Transcriptional Analysis of Parkinson's Disease. PLoS ONE, 2009, 4, e4955.	1.1	81
121	Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. Movement Disorders, 2009, 24, 111-115.	2.2	21
122	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. Movement Disorders, 2009, 24, 833-838.	2.2	56
123	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Movement Disorders, 2009, 24, 290-292.	2.2	23
124	Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease. Movement Disorders, 2009, 24, 448-452.	2.2	19
125	Validity of a selfâ€rated method to identify a lifetime history of depression in Parkinson's disease. Movement Disorders, 2009, 24, 2436-2438.	2.2	2
126	Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism and Related Disorders, 2009, 15, 105-109.	1.1	52

#	Article	IF	Citations
127	Prevalence of smell loss in Parkinson's disease â€“ A multicenter study. Parkinsonism and Related Disorders, 2009, 15, 490-494.	1.1	329
128	Haplotype analysis of the IGF2â€‰NSâ€‰TH gene cluster in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 495-499.	1.1	17
129	Utility of a patient survey in identifying fluctuations in early stage Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2008, 15, 1235-1239.	0.8	15
130	Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. Human Molecular Genetics, 2008, 17, 2863-2867.	1.4	21
131	Developing professional researchers: research studentsâ€™ graduate attributes. Studies in Continuing Education, 2007, 29, 19-36.	1.2	28
132	Association of APOE with Parkinson disease age-at-onset in women. Neuroscience Letters, 2007, 411, 185-188.	1.0	26
133	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 2007, 414, 170-173.	1.0	9
134	Validity of Hamilton depression inventory in Parkinson's disease. Movement Disorders, 2007, 22, 399-403.	2.2	39
135	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. Movement Disorders, 2007, 22, 982-989.	2.2	34
136	TNF Polymorphism and Cardiovascular Disease: TNF gene polymorphism and quantitative traits related to cardiovascular disease: getting to the heart of the matter. European Journal of Human Genetics, 2007, 15, 609-611.	1.4	10
137	Surfactant Protein Expression in Human Skin: Evidence and Implications. Journal of Investigative Dermatology, 2007, 127, 381-386.	0.3	31
138	Imagining an interdisciplinary doctoral pedagogy. Teaching in Higher Education, 2006, 11, 365-379.	1.7	76
139	Prevalence of Parkinsonâ€™s disease in metropolitan and rural Queensland: A general practice survey. Journal of Clinical Neuroscience, 2006, 13, 343-348.	0.8	32
140	Parkinson's disease and family history. Parkinsonism and Related Disorders, 2006, 12, 399-409.	1.1	56
141	Collaborative Analysis of Î±-Synuclein Gene Promoter Variability and Parkinson Disease. JAMA - Journal of the American Medical Association, 2006, 296, 661.	3.8	467
142	Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurology, The, 2006, 5, 917-923.	4.9	83
143	GPNN: power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease. BMC Bioinformatics, 2006, 7, 39.	1.2	75
144	Parkinson's Disease in Relation to Pesticide Exposure and Nuclear Encoded Mitochondrial Complex I Gene Variants. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-8.	3.0	17

#	Article	IF	Citations
145	Passive smoking and Parkinson disease. Neurology, 2006, 67, 179-180.	1.5	41
146	GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Annals of Neurology, 2005, 58, 829-839.	2.8	191
147	Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neuroscience Letters, 2005, 375, 112-116.	1.0	64
148	Testâ€“retest repeatability of self-reported environmental exposures in Parkinson's disease cases and healthy controls. Parkinsonism and Related Disorders, 2005, 11, 287-295.	1.1	19
149	Comparison of Environmental and Genetic Factors for Parkinsonâ€™s Disease between Chinese and Caucasians. Neuroepidemiology, 2004, 23, 13-22.	1.1	17
150	Glutathione transferase Omega class polymorphisms in Parkinson disease. Neurology, 2004, 62, 1910-1911.	1.5	23
151	Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics, 2004, 5, 115-119.	0.7	28
152	A novel screen for nuclear mitochondrial gene associations with Parkinson?s disease. Journal of Neural Transmission, 2004, 111, 191-199.	1.4	11
153	Tau haplotypes regulate transcription and are associated with Parkinson's disease. Annals of Neurology, 2004, 55, 329-334.	2.8	157
154	UCHL1 is a Parkinson's disease susceptibility gene. Annals of Neurology, 2004, 55, 512-521.	2.8	227
155	Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Annals of Neurology, 2004, 55, 897-897.	2.8	52
156	Late-onset presentation of pyruvate dehydrogenase deficiency. Movement Disorders, 2004, 19, 727-729.	2.2	43
157	Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinsonâ€™s disease. Neuroscience Letters, 2004, 366, 326-331.	1.0	64
158	Genetic and environmental risk factors and their interactions for Parkinsonâ€™s disease in a Chinese population. Journal of Clinical Neuroscience, 2003, 10, 313-315.	0.8	11
159	RELIABILITY OF SELF-REPORTED ENVIRONMENTAL EXPOSURE DATA IN AN EPIDEMIOLOGICAL STUDY OF PARKINSONÊ¼S DISEASE. Epidemiology, 2003, 14, S121-S122.	1.2	0
160	Age-Environment and Gene-Environment Interactions in the Pathogenesis of Parkinson's Disease. Reviews on Environmental Health, 2002, 17, 51-64.	1.1	55
161	The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neuroscience Letters, 2002, 327, 91-94.	1.0	57
162	Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population. Journal of Neural Transmission, 2002, 109, 35-39.	1.4	14

#	Article	IF	Citations
163	The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. Parkinsonism and Related Disorders, 2001, 7, 89-91.	1.1	21
164	Zeta class glutathione transferase polymorphisms and Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 407-407.	0.9	4
165	An isolated in-situ rat head perfusion model for pharmacokinetic studies. Pharmaceutical Research, 2000, 17, 127-134.	1.7	10
166	Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. Journal of Neural Transmission, 2000, 107, 979-983.	1.4	35
167	The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population. Journal of Neurology, 2000, 247, 52-55.	1.8	30
168	The Î±-Synuclein Gene and Parkinson Disease in a Chinese Population. Archives of Neurology, 2000, 57, 501.	4.9	30
169	The Serotonin Transporter Gene and Parkinsonâ€™s Disease. European Neurology, 2000, 44, 108-111.	0.6	7
170	The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neuroscience Letters, 2000, 293, 127-130.	1.0	56
171	The ACE Deletion Polymorphism Is Not Associated with Parkinsonâ€™s Disease. European Neurology, 1999, 41, 103-106.	0.6	22
172	No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1188-1191.	1.4	30
173	Structureâ€“Hepatic Disposition Relationships for Phenolic Compounds. Toxicology and Applied Pharmacology, 1999, 158, 50-60.	1.3	14
174	Movement Disorders, 1999, 14, 219-224.	2.2	82
175	Glutathione transferase polymorphism and Parkinson's disease. Lancet, The, 1999, 353, 71-72.	6.3	3
176	14, 219.		3
177	Hepatic Disposition and Metabolite Kinetics of a Homologous Series of Diflunisal Esters. Journal of Pharmaceutical Sciences, 1998, 87, 943-951.	1.6	12
178	Hepatic structure-pharmacokinetic relationships: The hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. British Journal of Pharmacology, 1998, 124, 1475-1483.	2.7	15
179	Focused antithrombotic therapy: Novel anti-platelet salicylates with reduced ulcerogenic potential and higher first-pass detoxification than aspirin in rats. Translational Research, 1998, 132, 469-477.	2.4	8
180	Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet, The, 1998, 352, 1344-1346.	6.3	303

#	Article	IF	Citations
181	Metabolite mean transit times in the liver as predicted by various models of hepatic elimination. Journal of Pharmacokinetics and Pharmacodynamics, 1997, 25, 477-505.	0.6	5
182	Synthesis, identification, characterization, stability, solubility, and protein binding of ester derivatives of salicylic acid and diflunisal. International Journal of Pharmaceutics, 1997, 153, 25-39.	2.6	13
183	Development of a Sensitive and Specific Radioimmunoassay for Benztropine. Journal of Pharmaceutical Sciences, 1993, 82, 1027-1032.	1.6	5
184	Oxidative Stress in Parkinson's Disease; Parallels Between Current Animal Models, Human Studies and Cells. , 0, , .		2